Drug class review on beta2-agonists final report
Beta2-agonists act primarily to relax airway smooth muscle by stimulating beta2-receptors, which in turn increase cyclic AMP and produce functional antagonism to bronchoconstriction. Long-term control medications for persons with asthma include corticosteroids, cromolyn sodium and nedocromil, methyl...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Portland, Or.
Oregon Health & Science University, Evidence-Based Practice Center
2006, c2006
|
| Series: | Drug class reviews
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Beta2-agonists act primarily to relax airway smooth muscle by stimulating beta2-receptors, which in turn increase cyclic AMP and produce functional antagonism to bronchoconstriction. Long-term control medications for persons with asthma include corticosteroids, cromolyn sodium and nedocromil, methylxanthines, leukotriene modifiers, and long-acting beta2-agonists (LABAs). Medications for quick relief of bronchoconstriction and acute symptoms include short-acting beta2-agonists (SABAs) and anticholinergics. COPD is a slowly progressive disease of the airways that is characterized by a gradual loss of lung function. Since airflow obstruction is present in all persons with COPD, bronchodilators (beta2-agonists, anticholinergic drugs, and methylxanthines) are a key part of therapy. The purpose of this review is to compare the benefits and harms of different beta2-agonists |
|---|---|
| Item Description: | "November 2006.". - "The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports." |
| Physical Description: | PDF file (198 p.) |